Item 8.01 Other Events.

On November 18, 2019, Karuna Therapeutics, Inc. (the "Company") announced results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The presentation containing the initial data from the Phase 2 clinical trial is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits





99.1      Press Release issued by Karuna Therapeutics, Inc., dated November 18,
        2019.

99.2      Company presentation, dated November 18, 2019.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses